Epidemiology of lung cancer prognosis: Quantity and quality of life

Methods in Molecular Biology

Volumn 471, Issue , 2009, Pages 469-486

  Yang, Ping ^a  

^a MAYO CLINIC   (United States)

Author keywords

Chemotherapy; Gene expression profiling; Non small cell lung cancer; Pharmacogenomics; Quality of life; Radiation therapy; Small cell lung cancer; Survival; Toxicity

Indexed keywords

DISEASE FREE SURVIVAL; HUMAN; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; LUNG TUMOR; PROGNOSIS; QUALITY OF LIFE; REVIEW; TREATMENT OUTCOME;

CARCINOMA, NON-SMALL-CELL LUNG; DISEASE-FREE SURVIVAL; HUMANS; LUNG NEOPLASMS; PROGNOSIS; QUALITY OF LIFE; SMALL CELL LUNG CARCINOMA; TREATMENT OUTCOME;

EID: 60349084045     PISSN: 10643745     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-59745-416-2_24     Document Type: Review

References (96)

1. Mountain, C. F. (1997) Revisions in the international system for staging lung cancer. Chest 111(6), 1710-17.
2. Yang, P., Allen, M. S., Aubry, M. C., Wampfler, J. A., Marks, R. S., Edell, E. S., Thibodeau, S. N., Adjei, A. A., Jett, J., and Deschamps, C. (2005) Clinical features of 5,628 primary lung cancer patients: experience at Mayo Clinic from 1997-2003. Chest 128, 452-62.
3. Nesbitt, J. C., Lee, J. S., Komaki, R. and Roth, J. A. (1997) Cancer of the lung, in Cancer Medicine (Holland, J. F., Frei, E., III, Bast, R. J., Kufe, D., Morton, D., and Weichselbaum, R., eds.), Williams & Wilkins, Baltimore, MD, pp. 1723-803.
4. Feld, R., Sagman, U., and LeBlanc, M. (1996) Staging and prognostic factors: Small cell lung cancer, in Lung Cancer: Principles and Practice (Pass, H. I., Mitchell, J. B., Johnson, D. H., and Turrisi, A. T., eds.), Lipincott-Raven Publishers, Philadelphia, PA, pp. 495-509.
5. Wozniak, A. J., and Gadgeel, S. M. (2007) Adjuvant treatment of non-small-cell lung cancer: how do we improve the cure rates further? Oncology 21, 164-71.
6. Rubin, P., Brasacchio, R., and Katz, A. (2006) Solitary metastases: illusion versus reality. Semin. Radiat. Oncol. 16, 120-30.
7. Martini, N., and Melamed, M. R. (1975) Multiple primary lung cancers. J. Thorac. Cardiovasc. Surg. 70, 606-12.
8. Scott, W. J. (2004) Metachronous lung cancer: the role of improved postoperative surveillance. J. Thorac. Cardiovasc. Surg. 127, 633-35.
9. Martini, N., Bains, M. S., Burt, M. E., Zakowski, M. F., McCormack, P., Rusch, V. W., and Ginsberg, R. J. (1995) Incidence of local recurrence and second primary tumors in resected stage I lung cancer. J. Thorac. Cardiovasc. Surg. 109(1), 120-29.
10. The Lung Cancer Study Group (1993) Malignant disease appearing late after operation for T1 N0 non-small cell lung cancer. J. Thorac. Cardiovasc. Surg. 106, 1053-58.
11. Immerman, S. C., Vanecko, R. M., Fry, W. A., Head, L. R., and Shields, T. W. (1981) Site of recurrence in patients with stages I and II carcinoma of the lung resected for cure. Ann. Thorac. Surg. 32, 23-27.
12. Martini, N., Rusch, V. W., Bains, M. S., Kris, M. G., Downey, R. J., Flehinger, B. J. and Ginsberg, R. J. (1999) Factors influencing ten-year survival in resected stages I to IIIA non-small lung cancer. J. Thorac. Cardiovasc. Surg. 117, 32-38.
13. Colice, G. L., Rubins, J., and Unger, M. (2003) Follow-up and surveillance of the lung cancer patient following curative-intent therapy. Chest 123,
14. Thomas, P., Rubinstein, L., and The Lung Cancer Study Group. (1990) Cancer Recurrence after resection: T1 N0 non-small cell lung cancer. Ann. Thorac. Surg. 49, 242-47.
15. Sugimura, H., Nichols, F. C., Yang, P., Allen, M. S., Deschamps, C., Cassivi, S. D., Williams, B. A., and Pairolero, P. C. (2007) Survival following recurrent non-small cell lung cancer after complete pulmonary resection. Ann Thorac. Surg. 83, 409-18.
16. Williams, B. A., Sugimura, H., Endo, C., Nichols, F. C., Cassivi, S. D., Allen, M. S., Pairolero, P. C., Deschamps, C., and Yang, P. (2006) Predicting postrecurrence survival among completely resected nonsmall-cell lung cancer patients. Ann.Thorac. Surg. 81, 1021-27.
17. Visbal, A. L., Williams, B. A., Nichols, F. C., Marks, R. S., Jett, J. R., Aubry, M. C., Edell, E. S., Wampfler, J. A., Molina, J. R., and Yang, P. (2004) Gender differences in non-small cell lung cancer survival: an analysis of 4,618 patients diagnosed between 1997-2002. Ann. Thorac. Surg. 78(1), 209-15.
18. Sun, Z., Aubry, M. C., Deschamps, C., Marks, R. S., Okuno, S. H., Williams, B. A., Sugimura, H., Pankratz, V. S. and Yang, P. (2006) Histologic grade is an independent prognostic factor for survival in non-small cell lung cancer: an analysis of 5018 hospital-and 712 population-based cases. J. Thorac. Cardiovasc. Surg. 131, 1014-20.
19. Ebbert, J. O., Yang, P., Vachon, C. M., Vierkant, R. A., Cerhan, J. R., Folsom, A. R., and Sellers, T. A. (2003) Lung cancer risk reduction after smoking cessation: observations from a prospective cohort of women. J. Clin. Oncol. 21(5), 921-26.
20. Jatoi, A., Williams, B., Nichols, F. C., Marks, R. S., Aubry, M. C., Wampfler, J., Finke, E. E., and Yang, P. (2005) Is voluntary vitamin and mineral supplementation associated with better outcome in non-small cell lung cancer? results from the Mayo Clinic lung cancer cohort. Lung Cancer 49, 77-84.
21. Jatoi, A., Williams, B. A., Marks, R., Nichols, F. C., Aubry, M. C., Wampfler, J., and Yang, P. (2005) Exploring vitamin and mineral supplementation and purported clinical effects in patients with small cell lung cancer: results from the Mayo Clinic lung cancer cohort. Nutr. Cancer 51, 7-12.
22. Brundage, M. D., Davies, D., and Mackillop, W. J. (2002) Prognostic factors in non-small cell lung cancer. A decade of progress. Chest 122(3), 1037-57.
23. Sun, Z., and Yang, P. (2006) Gene expression profiling on lung cancer outcome prediction: present clinical value and future premise. Cancer Epidemiol. Biomarkers Prev. 15, 2063-68.
24. Yanagisawa, K., Shyr, Y., Xu, B. J., Massion, P. P., Larsen, P. H., White, B. C., Roberts, J. R., Edgerton, M., Gonzalez, A., Nadaf, S., Moore, J. H., Caprioli, R. M., and Carbone, D. P. (2003) Proteomic patterns of tumour subsets in non-small-cell lung cancer. Lancet 362, 433-39.
25. Yanagisawa, K., Tomida, S., Shimada, Y., Yatabe, Y., Mitsudomi, T., and Takahashi, T. (2007) A 25-signal proteomic signature and outcome for patients with resected non-small-cell lung cancer. J. Natl. Cancer Inst. 99, 858-67.
26. Saijo, N. (2006) Recent trends in the treatment of advanced lung cancer. Cancer 97, 448-52.
27. Byrne, B. J., and Garst, J. (2005) Epidermal growth factor receptor inhibitors and their role in non-small-cell lung cancer. Curr. Oncol. Rep. 7, 241-47.
28. Shigematsu, H., and Gazdar, A. F. (2006) Somatic mutations of epidermal growth factor receptor signaling pathway in lung cancers. Int. J. Cancer. 118, 257-62.
29. Janne, P. A., Engelman, J. A., and Johnson, B. E. (2005) Epidermal growth factor receptor mutations in non-small-cell lung cancer: implications for treatment and tumor biology. J. Clin. Oncol. 23, 3227-34.
30. Calvo, E., and Baselga, J. (2006) Ethnic differences in response to epidermal growth factor receptor tyrosine kinase inhibitors. J. Clin. Oncol. 24, 2158-63.
31. Jain, R. K. (2003) Molecular regulation of vessel maturation. Nat. Med. 9, 685-93.
32. Molina, J. R., Adjei, A. A., and Jett, J. R. (2006) Advance in chemotherapy of non-small cell lung cancer. Chest 130, 1211-19.
33. Stinchcombe, T. E. and Socinski, M. A. (2007) Bevacizumab in the treatment of non-small-cell lung cancer. Oncogene 26, 3691-98.
34. Ruttinger, D., WInter, H., van den Engel, N. K., Hatz, R. A., Schlemmer, M., Phola, H., Grutzner, S., Schendel, D. J., Fox, B. A., and Jauch, K. W. (2006) Immunotherapy of lung cancer: an update. Onkologie 29, 33-38.
35. Blackhall, F. H., and Shepherd, F. A. (2007) Small cell lung cancer and targeted therapies. Curr. Opin. Oncol. 19, 103-08.
36. Cross, D., and Burmester, J. K. (2006) Gene therapy for cancer treatment: past, present and future. Clin. Med. Res. 4, 218-27.
37. Boulikas, T., and Vougiouka, M. (2003) Cisplatin and platinum drugs at the molecular level. Oncol. Rep. 10, 1163-682.
38. Rogatko, A., Babb, J. S., Wang, H., Slifker, M. J., and Hudes, G. R. (2004) Patient characteristics compete with dose as predictors of acute treatment toxicity in early phase clinical trials. Clin. Cancer Res. 10, 4645-51.
39. Di Maio, M., Gridelli, C., Gallo, C., Shepherd, F., Piantedosi, F., Cigolari, S., Manzione, L., Illiano, A., Barbera, S., Robbiati, S. F., Frontini, L., Piazza, E., Ianniello, G. P., Veltri, E., Castiglione, F., Rosetti, F., Gebbia, V., Seymour, L., Chiodini, P., and Perrone, F. (2005) Chemotherapy-induced neutropenia and treatment efficacy in advanced non-small-cell lung cancer: a pooled analysis of three randomised trials. Lancet Oncol. 6, 669-77.
40. Gurney, H. (2005) I don't underdose my patients . . . do I? Lancet Oncol. 6, 637-38.
41. Susman, E. (2004) Rash correlates with tumour respsone after cetuximab. Lancet Oncol. 5, 647.
42. Gurney, H. (2002) How to calculate the dose of chemotherapy. Br. J. Cancer 86, 297-302.
43. Rankin, E. M., Mill, L., Kaye, S. B., Atkinson, R., Cassidy, L., Cordiner, J., Cruickshank, D., Davis, J. R., Duncan, I. D., Fullerton, W., Habeshaw, T., Kennedy, J., Kennedy, R., Kitchener, H., MacLean, A., Paul, J., Reed, N., Sarker, T., Soukop, M., et al. (1992) A randomised study comapring standard dose carboplatin with chlorambucil and carboplatin in advanced ovarian cancer. Br. J. Cancer 65, 275-81.
44. Poikonen, P., Saarto, T., Lundin, J., Joensuu, H., and Blomqvist, C. (1999) Leucocyte nadir as a marker for chemotherapy efficacy in node-positive breast cancer treated with adjuvant CMF. Br. J. Cancer 80, 1763-66.
45. Ratain, M. J., and Relling, M. V. (2001) Gazing into a crystal ball-cancer therapy in the post-genomic era. Nat. Med. 7, 283-85.
46. Lord, P. G., and Papoian, T. (2004) Genomics and Drug Toxicity. Science 306, 57.
47. Yang, P., Ebbert, J. O., Sun, Z., and Weinshilboum, R. M. (2005) A role of the glutathione metabolic pathway in lung cancer treatment and prognosis: a review. J. Clin. Oncol. 24, 1761-69.
48. Fuertes, M. A., Castilla, J., Alonso, C. and Perez, J. M. (2003) Cisplatin biochemical mechanism of action: from cytotoxicity to induction of cell death through interconnections between apoptotic and necrotic pathways. Curr. Med. Chem. 10, 257-66.
49. Rosell, R., Taron, M., Camps, C., and Lopez-Vivanco, G. (2003) Influence of genetic markers on survival in non-small cell lung cancer. Drugs Today (Barc) 39, 775-86.
50. Zhou, W., Gurubhagavatula, S., Liu, G., Park, S., Neuberg, D. S., Wain, J. C., Lynch, T. J., Su, L., and Christiani, D. C. (2004) Excision repair cross-complementation group 1 polymorphism predicts overall survival in advanced non-small cell lung cancer patients treated with platinum-based chemotherapy. Clin. Cancer Res. 10, 4939-43.
51. Gurubhagavatula, S., Liu, G., Park, S., Zhou, W., Su, L., Wain, J. C., Lynch, T. J., Neuberg, D. S., and Christiani, D. C. (2004) XPD and XRCC1 genetic polymorphisms are prognostic factors in advanced non-small-cell lung cancer patients treated with platinum chemotherapy. J. Clin. Oncol. 22, 2594-601.
52. Ryu, J. S., Hong, Y. C., Han, H. S., Lee, J. E., Kim, S., Park, Y. M., Kim, Y. C., and Hwang, T. S. (2004) Association between polymorphisms of ERCC1 and XPD and survival in non-small-cell lung cancer patients treated with cisplatin combination chemotherapy. Lung Cancer 44, 311-6.
53. Connell, P. P., Kron, S. J., and Weichselbaum, R. R. (2004) Relevance and irrelevance of DNA damage response to radiotherapy. DNA Repair (Amst) 3, 1245-51.
54. Willers, H., Dahm-Daphi, J., and Powell, S. N. (2004) Repair of radiation damage to DNA. Br. J. Cancer 90, 1297-301.
55. Ross, G. M. (2002) Inducation of cell death by radiotherapy. Endocr. Relat. Cancer 6, 41-44.
56. Leslie, E. M., Deeley, R. G., and Cole, S. P. C. (2001) Toxicological relevance of the multidrug resistance protein 1, MRP1 (ABCC1) and related transporters. Toxicology 167, 3-23.
57. Danesi, R., De Braud, F., Fogli, S., Di Paolo, A., and Del Tacca, M. (2001) Pharmacogenetic determinants of anti-cancer drug activity and toxicity. Trends Pharmacol. Sci. 22, 420-26.
58. Strange, R. C., Jones, P. W., and Fryer, A. A. (2000) Glutathione S-trnasferase: genetics and role in toxicology. Toxicol. Lett. 112-113, 357-63.
59. Eaton, D. L., and Bammler, T. K. (1999) Concise Review of the glutathione s-transferases and their significance to toxicology. Toxicol. Sci. 49, 156-64.
60. O'Brien, M. L., and Tew, K. D. (1996) Glutathione and Related Enzymes in Multidrug Resistance. Eur. J. Cancer 6, 967-78.
61. Anonymous. (1995) The World Health Organization Quality of Life Assessment (WHOQOL). Position Paper from the World Health Organization. Soc. Sci. Med. 41, 1403-09.
62. Bonomi, A. E., Patrick, D. L., Bushnell, D. M., and Martin, M. (2000) Validation of the United States' Version of the World Health Organization Quality of Life (WHOQOL) Instrument. J. Clin. Epidemiol. 53, 1-12.
63. Li, W. W. L., Lee, T. W. and Yim, A. P. C. (2004) Quality of life after lung cancer resection. Thorac. Surg. Clin. 14, 353-65.
64. Ware, J. E., and Sherbourne, C. D. (1992) The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med. Care 30, 473-83.
65. McHorney, C. A., Ware, J. E., and Raczek, A. E. (1993) The MOS 36-Item Short-Form Health Survey (SF-36): II. Psychometric and clinical tests of validity in measuring physical and mental health constructs. Med. Care 31, 247-63.
66. Bergman, B., and Aaronson, N. K. (1995) Quality-of-life and cost-effectiveness assessment in lung cancer. Curr. Opin. Oncol. 7, 138-43.
67. Cella, D. F., Bonomi, A. E., Lloyd, S. R., Tulsky, D. S., Kaplan, E., and Bonomi, P. (1995) Reliability and validity of the Functional Assessment of Cancer Therapy-Lung (FACT-L) quality of life instrument. Lung Cancer 12, 199-200.
68. Hollen, P. J., Gralla, R. J., Kris, M. G., and Cox, C. (1994) Quality of life during clinical trials: conceptual model for the Lung Cancer Symptom Scale (LCSS). Support. Care Cancer 2, 213-22.
69. Montazeri, A., Gillis, C. H., and McEwen, J. (1998) Quality of life in patients with lung cancer. A review of literature from 1970-1995. Chest 113(2), 467-81.
70. Ganz, P. A., Figlin, R. A., Haskell, C. M., La Soto, N., Siau, J., and The UCLA Solid Tumor Study Group. (1989) Supportive care versus supportive care and combination chemotherapy in metastatic non-small cell lung cancer. Cancer 63, 1271-78.
71. Helsing, M., Bergman, B., Thaning, L., and Hero, U. (1998) Quality of Life and survival in patients with advanced non-small cell lung cancer receiving supportive care plus chemotherapy with carboplatin and etoposide or supportive care only. A multicentre randomized phase III trial. Eur. J. Cancer. 34(7), 1036-44.
72. Silvestri, G., Pritchard, R., and Weich, H. G. (1998) Preferences for chemotherapy in patients with advanced non-small cell lung cancer: descriptive study based on scripted interviews. Br. Med. J. 317, 771-75.
73. Karmakar, M. K., and Ho, A. M. (2004) Postthoracotomy pain syndrome. Thorac. Surg. Clin. 14, 345-52.
74. Stavraky, K. M., Donner, A. P., Kincade, J. E., and Stewart, M. A. (1988) The effect of psychosocial factors on lung cancer mortality at one year. J. Clin. Epidemiol. 41, 75-82.
75. Reck, M., von Pawel, J., Macha, H. N., Kaukel, E., Deppermann, K. M., Bonnet, R., Ulm, K., Hessler, S., and Gatzemeier, U. (2006) Efficient palliation in patients with small-cell lung cancer by a combination of paclitaxel, etoposide and carboplatin: Quality of life and 6-years'-follow-up results from a randomised phase III trial. Lung Cancer 53, 67-75.
76. Temel, J. S., Pirl, W. F., and Lynch, T. J. (2006) Comprehensive symptom management in patients with advanced-stage non-small-cell lung cancer. Clin. Lung Cancer 7, 241-49.
77. Sugimura, H., and Yang, P. (2006) Long-term survivorship in lung cancer. A review. Chest 29, 1088-97.
78. Institute, N. C. (ed.) (2002) SEER Cancer Statistics Review, 1973-1999. Bethesda, MD. http://seer.cancer.gov/csr/1973-1999/.
79. Winton, T. L., Livingston, R. B., Johnson, D., and et al. (2004) A prospective randomized trial of adjuvant vionrelbine (VIN) and cisplation (CIS) in completely resected stage 1B and II non small cell lung cancer (NSCLC) Intergroup JBR.10. 7018.
80. Strauss, G. M., Herndon, J., Maddaus, M. A., et al. (2004) Randomized clinical trial of adjuvant chemotherapy with paclitzxel and craboplatin following resection in stage IB non-small cell lung cancer (NSCLC): report of Cancer and Leukemia Group B (CALGB) protocol 9633. 7019.
81. Jacoulet, P., Depierre, A., Moro, D., Riviere, A., Milleron, B., Quoix, E., Ranfaing, E., Anthoine, D., Lafitte, J. J., Lebeau, B., Kleisbauer, J. P., F., M., Fournel, P., Zaegel, M., Leclerc, J. P., Garnier, G., Brambilla, E., and Capron, F. (1997) Long-term survivors of small-cell lung cancer (SCLC): a French multicenter study. Groupe d'Oncologie de Langue Francaise. Ann. Oncol. 8(10), 1009-14.
82. Ko, C. Y., Maggard, M., and Livingston, E. H. (2003) Evaluating health utility in patients with melanoma, breast cancer, colon cancer, and lung cancer: a nationwide, population-based assessment. J. Surg. Res. 114, 1-5.
83. Johnson, B. E., Cortazar, P., and Chute, J. P. (1997) Second lung cancers in patients successfully treated for lung cancer. Semin. Oncol. 24, 492-99.
84. Johnson, B. E. (1998) Second lung cancers in patients after treatment for an initial lung cancer. J. Natl. Cancer Inst. 90(18), 1335-45.
85. Tucker, M. A., Murray, N., Shaw, E. G., Ettinger, D. S., Mabry, M., Huber, M. H., Feld, R., Shepherd, F. A., Johnson, D. H., Grant, S. C., Aisner, J., and Johnson, B. E. (1997) Second primary cancers related to smoking and treatment of small-cell lung cancer. J. Natl. Cancer Inst. 89(23), 1782-88.
86. Sarna, L., Evangelista, L., Tashkin, D., Padilla, G., Holmes, C., Brecht, M. L., and Grannis, F. (2004) Impact of respiratory symptoms and pulmonary function on quality of life of long-term survivors of non-small cell lung cancer. Chest 125(2), 439-45.
87. Myers, J. N., O'Neil, K. M., Walsh, T. E., Hoffmeister, K. J., Venzon, D. J. and Johnson, B. E. (2005) The pulmonary status of patients with limited-stage small cell lung cancer 15 years after treatment with chemotherapy and chest irradiation. Chest 128, 3261-68.
88. Pinto, B. M., Eakin, E., and Maruyama, N. (2000) Health behavior changes after a cancer diagnosis: what do we know and where do we go from here? Ann. Behav. Med. 22, 38-52.
89. Gritz, E. R., Nisenbaum, R., Elashoff, R. E., and Holmes, E. C. (1991) Smoking behavior following diagnosis in patients with stage I non-small cell lung cancer. Cancer Causes Control 2, 105-12.
90. Yang, P., Sugimura, H., Ebbert, J. O., Nichols, F. C., Kelemen, L. E., Worra, J. B., Stoddard, S. M., Johnson, M. E., and Sloan, J. A. (2004). Characteristics of long-term lung term lung cancer survivors. In: Department of Health and Human Services. National Cancer Institute, and American Cancer Society (eds.), Canon Survirorship: Pathways to Health After Treatment, pp. 51 Washington, DC.
91. Evangelista, L. S., Sarna, L., Brecht, M. L., Padilla, G., and Chen, J. (2003) Health perceptions and risk behaviors of lung cancer survivors. Heart Lung 32(2), 131-39.
92. Sarna, L., Padilla, G., Holmes, C., Tashkin, D., Brecht, M. L. and Evangelista, L. (2002) Quality of life of long-term survivors of non-small-cell lung cancer. J. Clin. Oncol. 20(13), 2920-29.
93. Yang, P., Sugimura, H., Sloan, J., Williams, B., Cassivi, S., Garces, Y., Sun, Z., Worra, J., Midthun, D., and Jatoi, A. (2005) Longitudinal evaluation of quality of life in long-term lung cancer survivors (Abstract), in 11th World Conference on Lung Cancer, Presidential Symposium, July 3-6, 2005, Barcelona, Spain. Lung Cancer 49, S4.
94. Kaasa, S., Mastekaasa, A., and Lund, E. (1989) Prognostic factors for patients with inoperable non-small cell lung cancer, limited disease. Radiother. Oncol. 15, 235-42.
95. Aziz, N. M. (2002) Cancer survivorship research: challenge and opportunity. J. Nutr. 132, 3494S-503S.
96. Wilson, I. B., and Cleary, P. D. (1995) Linking clinical variables with health-related quality of life: A conceptual model of patient outcomes. Jama 273, 59-65.